Friday, July 10, 2026

pharma · Retinitis Pigmentosa · Dyslipidaemia

HRA Pharma

Laboratoire HRA Pharma is a pharma organization headquartered in CHATILLON, FR. Primary therapeutic focus areas include Retinitis Pigmentosa, Dyslipidaemia, Hemophilia, Allergic Conjunctivitis, Leber congenital amaurosis

CHATILLON, USA HQ
121 Employees
EMA registrant Type
Company details
Status
Public
HQ
CHATILLON, USA
Employees
121
Programs
11
Drugs
17
Patents
0
Clinical program

Verkazia 1 mg/mL eye drops, emulsion

Phase 2 · small molecule · Vernal Keratoconjunctivitis (VKC)

Verkazia 1 mg/mL eye drops, emulsion for Vernal Keratoconjunctivitis (VKC) is a Phase 2 program (small_molecule) at Laboratoire HRA Pharma with 1 ClinicalTrials.gov record(s).

← All Laboratoire HRA Pharma projects Phase 2 small molecule active

Internal code LT1695-201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Laboratoire HRA Pharma
Phase
Phase 2
Modality
small_molecule
Indication
Vernal Keratoconjunctivitis (VKC)
Status
active
Trials
1